Journals / Tüberküloz ve Toraks / 2008 / Cilt: 56 - Sayı: 4

Tuberculous pleurisy after tumour necrosis factor-a antagonist usage: Case report

Tümör nekroz faktörü-α antagonisti kullanımı sonrası gelişen tüberküloz plörezi: Olgu sunumu

Pages
448–452
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

After one month, pleural fluid was markedly reduced.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A thirty-six year old male patient presented with dyspnea, right-sided chest pain, night sweats and intermittent fever.
📊
Key Findings & Data:The adenosine deaminase level of the pleural fluid was 110 U/L.
💡
Conclusion & Impact:After one month, pleural fluid was markedly reduced.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A thirty-six year old male patient presented with dyspnea, right-sided chest pain, night sweats and intermittent fever. He has a history of ankylosing spondylitis treated with tumour necrosis factor-alpha (TNF-a) antagonist (infliximab). Computed tomography of the chest showed mediastinal lymphadenopathy, right-sided pleural effusion, and atelectasis. The pleural fluid was exudative with lymphocyte dominance. Closed pleural biopsy was nondiagnostic. The adenosine deaminase level of the pleural fluid was 110 U/L. In light of these findings, the patient was diagnosed as tuberculous pleurisy and antituberculous treatment was given. After one month, pleural fluid was markedly reduced.

Özet

Otuz altı yaşında erkek hasta, nefes darlığı, sağ yan ağrısı, gece terlemesi, ara sıra olan yüksek ateş yakınmalarıyla başvurdu. Özgeçmişinde, ankilozan spondilit nedeniyle tümör nekroz faktörü-alfa (TNF-a) antagonisti (infliksimab) kullanım öyküsü vardı. Toraks bilgisayarlı tomografisinde mediastinal lenfadenopati, sağda plevral efüzyon ve atelektazi saptandı. Plevra sıvısı eksüda karakterindeydi. Sitolojik incelemede lenfosit hakimiyeti saptandı. Plevra biyopsisi ile tanı konamadı. Plevral sıvıda adenozin deaminaz (ADA) düzeyi 110 U/L bulundu. Olgu tüberküloz plörezi olarak kabul edildi ve antitüberküloz tedavi başlandı. Bir ay sonraki kontrolde, sıvıda belirgin gerileme saptandı.

🔖

Cite This Article

BABAYİĞİT, C., HANTA, İ., KARAZİNCİR, S., AKOĞLU, S., BALCI, A. (2022). Tuberculous pleurisy after tumour necrosis factor-a antagonist usage: Case report. Tüberküloz ve Toraks, Cilt: 56 - Sayı: 4, 448–452. https://ajindex.com/articles/619113

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Botsios C. Safety of tumour necrosis factor and interleukin- 1 blocking agents in rheumatic diseases. Autoimmunity Reviews 2005; 4: 162-70
  2. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-α antagonists. Medicine 2005; 84: 291-302
  3. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanism of action and clinical management. Lancet Infect Dis 2003; 3: 148-55
  4. King TE, Cherniak RM, Schwarz MI. The lungs and connective tissue diseases. In: Murray JF, Nadel JA (eds). Textbook of Pulmonary Medicine. 2nd ed. Philadelphia: WB Saunders Company, 1994: 1865-6
  5. Rosenow E, Strimlan CV, Muhm JR, et al. Pleuropulmonary manifestations of ankylosing spondylitis. Mayo Clin Proc 1977; 52: 641-9
  6. Foon KA, Fisher RI. Lymphomas. In: Beutler E, Lichtman MA, Cooler BS, Kipps TJ (eds). Williams Hematology. New York: McGraw-Hill, 1995: 1081
  7. Armitage JO, Mauch PM, Haris NL, Bierman P. Non- Hodgkin’s lymphomas. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2001: 2302-3
  8. Benucci M, Gobbi FL, Fossi F, et al. Drug-induced lupus after treatment with Infliximab in rheumatoid arthritis. JCR 2005; 11: 47-9
  9. Oksel F. Sistemik lupus eritematosus. Gümüşdiş G (editör). Klinik Romatoloji. İstanbul, 1999: 297
  10. Furin JJ, Johnson JL. Recent advances in the diagnosis and management of tuberculosis. Curr Opin Pulm Med 2005; 11: 189-94
  11. Long R, Gardam M. Tumour necrosis factor-α inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003; 168: 1153-6
  12. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumour necrosis factor antagonists. Arthritis&Rheumatism 2005; 52: 1766-72
  13. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006; 174: 736-42
  14. Wong PC. Management of tuberculous pleuritis: Can we do better? Respirology 2005; 10: 144-8
  15. Laborin RL. Adenosine deaminase in the diagnosis of tuberculous pleural effusion. Chest 2005; 127: 417-8.